Mathew Aby J.

Mathew Aby J., EVP & Chief Scientific Officer, has demonstrated a consistent pattern of selling shares in BioLife Solutions (BLFS) over the past two years, with no recorded purchases in SEC filings. Since March 2024, he has executed 18 sales totaling approximately $749,724, with transactions ranging from smaller dispositions—such as $2,442 on February 12, 2025, and $2,174 on May 17, 2024—to more substantial sales, including a $108,249 transaction on March 12, 2024, and a $353,000 disposition on February 24, 2026. The latter represents his largest single sale to date. Notably, his activity has accelerated recently, with three sales in the first quarter of 2026 alone, including a $43,116 transaction on March 19, 2026, and a $10,971 sale on March 3, 2026. All of Aby’s transactions have been concentrated in BLFS, where he holds an executive role, with no diversification into other securities. The filings include several awards (coded "A") with zero reported value, likely representing equity grants rather than market purchases. The absence of any buys suggests a one-directional trend toward reducing his position in the company. While the sales vary in size, their frequency—particularly in early 2026—indicates a sustained disposition strategy rather than isolated liquidity events. The consistency of this pattern over multiple years underscores a clear bias toward divestment rather than accumulation.